Synergistic inhibition of human immunodeficiency virus type 1 replication by 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and azidothymidine in vitro.

Abstract

A novel 6-substituted acyclouridine derivative, 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU), has recently proved to be a highly potent and selective inhibitor of human immunodeficiency virus type 1 (HIV-1) in vitro. Combinations of 3'-azido-2',3'-dideoxythymidine (AZT) and E-EPU synergistically inhibit the replication of HIV-1 in MT-4 cells, whereas the cytotoxic effects of AZT and E-EPU on mock-infected MT-4 cells are not enhanced by the drug combination. Synergistic inhibition of HIV-1 replication has also been observed in peripheral blood lymphocytes. These results indicate that the combination of AZT and E-EPU should be further pursued in the treatment of AIDS.

• Authors: M Baba, M Ito, S Shigeta, H Tanaka, T Miyasaka, M Ubasawa, K Umezu, R T Walker, E De Clercq
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 35 Issue 7 Pg. 1430-3 (Jul 1991) ISSN: 0066-4804 [Print] United States
• PMID: 1929304 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antiviral Agents
• 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil
• Zidovudine
• Uracil

Topics

• Antiviral Agents (pharmacology)
• Cells, Cultured
• Cytopathogenic Effect, Viral (drug effects)
• Drug Synergism
• HIV-1 (drug effects, physiology)
• Humans
• Uracil (analogs & derivatives, pharmacology)
• Virus Replication (drug effects)
• Zidovudine (pharmacology)